<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279747</url>
  </required_header>
  <id_info>
    <org_study_id>107.208</org_study_id>
    <nct_id>NCT00279747</nct_id>
  </id_info>
  <brief_title>A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)</brief_title>
  <official_title>A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      A one year double-blind trial to investigate the efficacy and safety of meloxicam oral&#xD;
      suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral&#xD;
      suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: In an international, multicenter, double-blind, randomized clinical trial we&#xD;
      evaluated the short-term (3 months) and long term (12 months) efficacy and safety of two&#xD;
      doses of meloxicam oral suspension compared with naproxen in children with oligo and&#xD;
      polyarticular course juvenile idiopathic arthritis (JIA).&#xD;
&#xD;
      Methods: Children with active oligo or polyarticular course JIA, requiring therapy with an&#xD;
      NSAID were eligible for this trial. Patients were randomly allocated to therapy with&#xD;
      meloxicam oral suspension 0.125 mg/kg body weight in single daily dose, meloxicam 0.25 mg/kg&#xD;
      body weight in single daily dose, or naproxen 10 mg/kg body weight in two daily doses. The&#xD;
      trial drugs were administered in a double-blind, double-dummy design for up to 12 months.&#xD;
      Response rates were determined according to the American College of Rheumatology Pediatric&#xD;
      30% definition of improvement (ACR Ped 30). Safety parameters were assessed by evaluation of&#xD;
      the adverse events in the 3 groups.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      The null hypothesis of interest is that the magnitude of response with regard to the primary&#xD;
      endpoint is equivalent between the treatment groups. The alternative is that there is any&#xD;
      difference (two-sided) between any of the treatment groups.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      Naproxen oral suspension 10 mg/kg body weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rates according to ACR Ped 30</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment of overall disease activity by investigator</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent global assessment of overall well-being</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of functional disability by means of Childhood Health Assessment Questionnaire (CHAQ)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of joints with active arthritis</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of joints with limited range of motion</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent global assessment of arthritis</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent global assessment of pain</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's assessment of discomfort</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional classification (Steinbrocker classification)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by parent</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by investigator</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals due to inadequate efficacy</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol / acetaminophen consumption</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by parent</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by investigator</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events (AEs)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal due to adverse event</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay due to gastrointestinal serious adverse event (GI-SAE)</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay due to adverse events related to trial drug administration</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional visits to a physician due to gastrointestinal adverse event (GI-AE)</measure>
    <time_frame>week 12, 12 months</time_frame>
  </secondary_outcome>
  <enrollment>226</enrollment>
  <condition>Arthritis, Juvenile Rheumatoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meloxicam 0.25 mg/kg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meloxicam 0.125 mg/kg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen 10 mg/kg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female outpatients and inpatients aged 2 to 16 years&#xD;
&#xD;
          -  Diagnosis of idiopathic arthritis of childhood by ILAR criteria:&#xD;
&#xD;
               -  Age of onset less than 16 years&#xD;
&#xD;
               -  Arthritis in one or more joints defined as swelling, or - if no swelling is&#xD;
                  present - limitation in range of joint movement with joint pain or tenderness,&#xD;
                  which is not due to primary mechanical disorders&#xD;
&#xD;
               -  Duration of the disease &gt; 6 weeks&#xD;
&#xD;
               -  Type of onset of disease during the first 6 months classified as polyarthritis (5&#xD;
                  joints or more; rheumatoid factor positive or negative), oligoarthritis (4 joints&#xD;
                  or fewer) or systemic arthritis&#xD;
&#xD;
          -  Oligoarthritic, extended oligoarthritic or polyarthritic current course of disease&#xD;
&#xD;
          -  Active arthritis as defined above of at least 2 joints&#xD;
&#xD;
          -  At least 2 other abnormal variables of any of the 5 remaining core set parameters. The&#xD;
             physician and the parent ratings must be at least 10 mm on a 100 mm VAS scale and the&#xD;
             CHAQ score more than 0.&#xD;
&#xD;
          -  Patients requiring therapy with NSAIDs, i.e., the patient fits into one of the&#xD;
             following categories:&#xD;
&#xD;
               -  New onset patient&#xD;
&#xD;
               -  Patient in remission, but experiencing a flare and now requiring an NSAID&#xD;
&#xD;
               -  Patient with insufficient therapeutic effect (ITE) or intolerability to another&#xD;
                  NSAID (other than Naproxen) and now must be changed&#xD;
&#xD;
          -  Written informed permission given by the parent(s) or the subjects legally authorised&#xD;
             representative in accordance with local legislation and ICH GCP&#xD;
&#xD;
          -  Active assent given by the patient if the child is capable of understanding the given&#xD;
             information (applies to children who have reached an intellectual age of 7 years or&#xD;
             greater)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with systemic course of JRA (intermittent fever with or without rash or other&#xD;
             organ involvement) or with current systemic involvement&#xD;
&#xD;
          -  All rheumatic diseases not covered by the inclusion criteria&#xD;
&#xD;
          -  Any finding indicating that the patient has a clinically significant other disease&#xD;
             than JRA at the time of enrollment&#xD;
&#xD;
          -  Patients with abnormal, clinically relevant laboratory values not related to their JRA&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Women of childbearing potential not using adequate contraception precaution: attention&#xD;
             should be drawn to reports that NSAIDs were reported to decrease the effectiveness of&#xD;
             intrauterine devices (R95-0164)&#xD;
&#xD;
          -  History of bleeding disorders, gastrointestinal bleeding or cerebrovascular bleeding&#xD;
&#xD;
          -  Active peptic ulcer within the last 6 months&#xD;
&#xD;
          -  Treatment with more than one SAARD/DMARD (slow-acting antirheumatic&#xD;
             drug/disease-modifying antirheumatic drug) during the last 3 months prior to study&#xD;
             entry&#xD;
&#xD;
          -  Change in treatment with SAARDs/DMARDs during the last 3 months prior to study entry&#xD;
             or intended change during the trial duration&#xD;
&#xD;
          -  Change in treatment with corticosteroids during the last month prior to study entry or&#xD;
             intended change during the trial duration with exception of local therapy for uveitis&#xD;
&#xD;
          -  One of the following therapies during the last 3 months prior to study entry or their&#xD;
             intended use during the trial treatment period&#xD;
&#xD;
               -  Systemic treatment (except for intra-articular injections) with corticosteroids&#xD;
                  at a dose higher than 10 mg/day or 0.2 mg/kg/day (prednisone equivalent),&#xD;
                  respectively (whichever is lower)&#xD;
&#xD;
               -  Treatment with hydroxychloroquine at a dose higher than 10 mg/kg/day&#xD;
&#xD;
               -  Treatment with cyclosporine at a dose higher than 5 mg/kg/day&#xD;
&#xD;
               -  Treatment with methotrexate at a dose higher than 15 mg/m2/week&#xD;
&#xD;
               -  Treatment with other cytotoxic agents, gold compounds, D-penicillamine, Enbrel&#xD;
                  (etanercept), biologic agents and experimentals&#xD;
&#xD;
          -  Intra-articular injections of corticosteroids during the last month prior to study&#xD;
             entry and intended injections during the first 4 weeks of the trial treatment period&#xD;
&#xD;
          -  Concomitant administration of other NSAIDs (including topical forms for skin with&#xD;
             exception of local therapy for uveitis) or analgesic agents except paracetamol or&#xD;
             acetaminophen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Pharma GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landes-Kinderklinik Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Kinder- und Jugendheilkunde Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottfried Preyersches Kinderspital d. Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1100 Wien</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumaklinik Bad Bramstedt GmbH</name>
      <address>
        <city>Bad Bramstedt</city>
        <zip>24572</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie</name>
      <address>
        <city>Bremen</city>
        <zip>28325</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayrische Julius-Maximilians-Universität</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto G. Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II Università degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica I</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Burlo Garofalo</name>
      <address>
        <city>Trieste</city>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology of RAMN</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Faculty of Russian People Friendship University</name>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Pediatric Hematology</name>
      <address>
        <city>Moscow</city>
        <zip>117513</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy Setchenov</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Child Health</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Hall Childrens Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M9 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paediatric Department</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.208_U03-1727.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.208_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 19, 2006</study_first_submitted>
  <study_first_submitted_qc>January 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2006</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

